SCHEMBL18310484

SCHEMBL18310484

CCCc1ccc(-c2ccc(-c3cc(F)c(-c4cc(F)c(OCF)c(F)c4)c(F)c3)c(F)c2)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.35
RARB P10826 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GABRA1 P14867 2/20 0.33
GABRB2 P47870 2/20 0.33
FFAR4 Q5NUL3 2/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
S1PR1 P21453 2/20 0.31
S1PR3 Q99500 2/20 0.31
ALOX5AP P20292 2/20 0.31
FEN1 P39748 2/20 0.31
CHKA P35790 1/20 0.30
FAAH O00519 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18310417 0.97 CNR1 (0.33) ALOX5RARBNPC1TP53PKM
SCHEMBL18310413 0.95 ALOX5 (0.38) ALOX5RARBNPC1TP53PKM
SCHEMBL18310571 0.95 ALOX5 (0.38) ALOX5RARBNPC1TP53PKM
SCHEMBL18310477 0.93 RARB (0.37) RARBNPC1TP53PKMRAB9A
SCHEMBL18310375 0.92 CNR1 (0.37) ALOX5RARBNPC1TP53PKM
SCHEMBL18310478 0.88 RARB (0.39) ALOX5RARBNPC1TP53PKM
SCHEMBL18310483 0.87 RARB (0.40) ALOX5RARBNPC1TP53PKM
SCHEMBL18310409 0.87 RARB (0.40) ALOX5RARBNPC1TP53PKM
SCHEMBL19829089 0.85 RARB (0.37) RARBNPC1TP53PKMRAB9A
SCHEMBL18310380 0.85 NPC1 (0.32) NPC1TP53PKMRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951277-B2 Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2018-04-24 US disclosed
US-20180030351-A1 LIQUID CRYSTAL COMPOUND HAVING POLYFLUORO-2-BUTENOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-02-01 US disclosed
US-20160362605-A1 LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362605-A1 LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE TCOF1, PIEZO1, RCC1 ALOX5 761/4885RARB 2668/4885NPC1 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.